Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era

  • Shee K
  • Muller K
  • Marotti J
  • et al.
N/ACitations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Historically, ductal carcinoma in situ (DCIS) of the breast has been managed aggressively with surgery and radiotherapy because of a risk of progression to invasive ductal carcinoma. However, this treatment paradigm has been challenged by overtreatment concerns and evidence that suggests that DCIS can be stratified according to risk of recurrence or risk of progression to invasive disease. Traditional methods of risk stratification include histologic grade and hormone receptor status. Recent technological advancements have enabled an era of precision medicine, where DCIS can be molecularly analyzed by tools, such as next-generation DNA and RNA sequencing, to identify molecular biomarkers for risk stratification. These findings have led to the development of tools such as the Oncotype DX Breast DCIS Score, a gene expression–based assay with the potential to prevent overtreatment in low-risk disease.

Cite

CITATION STYLE

APA

Shee, K., Muller, K. E., Marotti, J., Miller, T. W., Wells, W. A., & Tsongalis, G. J. (2019). Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era. The American Journal of Pathology, 189(5), 956–965. https://doi.org/10.1016/j.ajpath.2018.08.020

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free